• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ixekizumab in hidradenitis suppurativa in a psoriatic patient.

作者信息

Odorici Giulia, Pellacani Giovanni, Conti Andrea

机构信息

Unit of Dermatology, Department of Surgical, Medical, Dental and Morphological Sciences with Interest Transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy -

Unit of Dermatology, Department of Surgical, Medical, Dental and Morphological Sciences with Interest Transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy.

出版信息

G Ital Dermatol Venereol. 2020 Dec;155(6):788-789. doi: 10.23736/S0392-0488.18.06135-7. Epub 2019 Jan 9.

DOI:10.23736/S0392-0488.18.06135-7
PMID:30636397
Abstract
摘要

相似文献

1
Ixekizumab in hidradenitis suppurativa in a psoriatic patient.司库奇尤单抗治疗一名银屑病患者的化脓性汗腺炎
G Ital Dermatol Venereol. 2020 Dec;155(6):788-789. doi: 10.23736/S0392-0488.18.06135-7. Epub 2019 Jan 9.
2
No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: A report from 16 clinical studies of patients with psoriasis or psoriatic arthritis.接受司库奇尤单抗治疗的潜伏性结核感染患者未出现结核病再激活：来自16项银屑病或银屑病关节炎患者临床研究的报告
J Am Acad Dermatol. 2020 Nov;83(5):1436-1439. doi: 10.1016/j.jaad.2020.06.012. Epub 2020 Jun 8.
3
Concomitant psoriasis and hidradenitis suppurativa responsive to adalimumab therapy: A case series.阿达木单抗治疗伴发银屑病和化脓性汗腺炎有效：一组病例报告。
Indian J Dermatol Venereol Leprol. 2021 Mar-Apr;87(2):223-226. doi: 10.4103/ijdvl.IJDVL_455_18.
4
Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after anti-TNF failure.抗TNF治疗失败后使用布罗达单抗成功治疗顽固性臀部化脓性汗腺炎。
Int J Dermatol. 2020 Jun;59(6):733-735. doi: 10.1111/ijd.14792. Epub 2020 Feb 3.
5
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.司库奇尤单抗，一种白细胞介素-17A特异性单克隆抗体，用于治疗初治的活动性银屑病关节炎患者：III期试验SPIRIT-P1的24周随机、双盲、安慰剂对照及活性（阿达木单抗）对照阶段的结果
Ann Rheum Dis. 2017 Jan;76(1):79-87. doi: 10.1136/annrheumdis-2016-209709. Epub 2016 Aug 23.
6
Successful use of guselkumab in the treatment of severe hidradenitis suppurativa.古塞库单抗成功用于治疗重度化脓性汗腺炎。
Clin Exp Dermatol. 2020 Jul;45(5):618-619. doi: 10.1111/ced.14199. Epub 2020 Mar 30.
7
PsAPASH: a new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition.化脓性汗腺炎相关新综合征PsAPASH：对肿瘤坏死因子抑制有反应
J Am Acad Dermatol. 2015 Jan;72(1):e42-4. doi: 10.1016/j.jaad.2014.10.002.
8
Endometrium cancer in a female with psoriatic arthritis treated with TNF alpha antagonist adalimumab.一名患有银屑病关节炎的女性在接受肿瘤坏死因子α拮抗剂阿达木单抗治疗后发生子宫内膜癌。
Rheumatol Int. 2011 Nov;31(11):1537-8. doi: 10.1007/s00296-010-1661-5. Epub 2010 Dec 1.
9
Long-term retention rates of anti-tumour necrosis factor and anti-interleukin-17 antibodies for patients with psoriatic arthritis.抗肿瘤坏死因子和抗白细胞介素-17 抗体治疗银屑病关节炎患者的长期保留率。
Mod Rheumatol. 2024 Aug 20;34(5):1013-1018. doi: 10.1093/mr/road111.
10
Inverse psoriasis on pre-existing hidradenitis suppurativa lesions: Reply to "A case series of tumor necrosis factor inhibitor-induced psoriasis in patients with hidradenitis suppurativa".预先存在的化脓性汗腺炎皮损上出现的反向银屑病：对“化脓性汗腺炎患者中肿瘤坏死因子抑制剂诱发银屑病的病例系列”的回复
Dermatol Online J. 2024 Jun 15;30(3). doi: 10.5070/D330363884.

引用本文的文献

1
Hidradenitis suppurativa and psoriasis: the odd couple.化脓性汗腺炎与银屑病：这一奇特组合。
Front Med (Lausanne). 2023 Jul 7;10:1208817. doi: 10.3389/fmed.2023.1208817. eCollection 2023.
2
Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies.化脓性汗腺炎的新兴治疗方法及临床试验概况 第一部分：局部和全身药物治疗
Dermatol Ther (Heidelb). 2023 Aug;13(8):1661-1697. doi: 10.1007/s13555-023-00956-6. Epub 2023 Jul 4.
3
New Insight into the Molecular Pathomechanism and Immunomodulatory Treatments of Hidradenitis Suppurativa.
深入了解化脓性汗腺炎的分子发病机制和免疫调节治疗。
Int J Mol Sci. 2023 May 8;24(9):8428. doi: 10.3390/ijms24098428.
4
Immunomodulatory Drugs in the Treatment of Hidradenitis Suppurativa-Possibilities and Limitations.免疫调节药物治疗化脓性汗腺炎：可能性与局限性。
Int J Mol Sci. 2022 Aug 26;23(17):9716. doi: 10.3390/ijms23179716.
5
An Anti-Interleukin-17A Monoclonal Antibody, Ixekizumab, in the Treatment of Resistant Hidradenitis Suppurativa: A Case Series.抗白细胞介素-17A单克隆抗体司库奇尤单抗治疗难治性化脓性汗腺炎：病例系列
Skin Appendage Disord. 2022 Jul;8(4):342-345. doi: 10.1159/000521860. Epub 2022 Feb 9.
6
IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept study.IL-17A 是中重度化脓性汗腺炎的一个有针对性的治疗靶点：临床前和 II 期概念验证研究的综合结果。
Exp Dermatol. 2022 Oct;31(10):1522-1532. doi: 10.1111/exd.14619. Epub 2022 Aug 19.
7
New and Emerging Targeted Therapies for Hidradenitis Suppurativa.化脓性汗腺炎的新型及新兴靶向治疗方法
Int J Mol Sci. 2022 Mar 29;23(7):3753. doi: 10.3390/ijms23073753.
8
Paradoxical Hidradenitis Suppurativa during Biologic Therapy, an Emerging Challenge: A Systematic Review.生物治疗期间的反常性化脓性汗腺炎：一项新出现的挑战——系统评价
Biomedicines. 2022 Feb 16;10(2):455. doi: 10.3390/biomedicines10020455.
9
New perspectives on the treatment of hidradenitis suppurativa.化脓性汗腺炎治疗的新视角。
Ther Adv Chronic Dis. 2021 Nov 23;12:20406223211055920. doi: 10.1177/20406223211055920. eCollection 2021.
10
Insights into the Pathogenesis of HS and Therapeutical Approaches.化脓性汗腺炎发病机制及治疗方法的见解。
Biomedicines. 2021 Sep 6;9(9):1168. doi: 10.3390/biomedicines9091168.